

FAMILY/DRUG NAME	MECHANISM	COMPANY	STATUS
Interferons - Mimic naturally-occurring, infection-fighting immune substances produced in the body			
Intron A (Interferon alfa-2b)	Immunomodulator	Merck, Whitehouse Station, NJ	FDA Approved 1991
Pegasys (Peginterferon alfa-2a)	Immunomodulator	Genentech, South San Francisco, CA	FDA Approved 2005
<i>There are other brands of interferon approved for HCV treatment, but they have not been FDA-approved for HBV: Wellferon (Glaxo), Roferon (Hoffman-La Roche), and Infergen (Amgen)</i>			
Nucleoside Analogues - Interfere with the viral DNA polymerase enzyme used for hepatitis B virus reproduction			
Epivir-HBV (Lamivudine)	Inhibits viral DNA polymerase	GlaxoSmithKline, Philadelphia, PA	FDA Approved 1998
Hepsera (Adefovir Dipivoxil)	Inhibits viral DNA polymerase	Gilead Sciences, Foster City, CA	FDA Approved 2002
Baraclude (Entecavir)	Inhibits viral DNA polymerase	Bristol-Myers Squibb, Princeton, NJ	FDA Approved 2005
Tyzeka (Telbivudine)	Inhibits viral DNA polymerase	Novartis, Switzerland	FDA Approved 2006
Viread (Tenofovir)	Inhibits viral DNA polymerase	Gilead Sciences, Foster City, CA	FDA Approved 2008
Clevudine (L-FMAU)	Inhibits viral DNA polymerase	Bukwang, South Korea Eisai, Japan	Approved S. Korea 2006 (Levovir)
Tenofovir alafenamide (TAF)	Prodrug of Tenofovir	Gilead Sciences, Foster City, CA	Phase III
CMX157	Prodrug of Tenofovir	ContraVir Pharmaceuticals, Edison, NJ	Phase II
AGX-1009	Prodrug of Tenofovir	Cinkate Pharma Oak Park, IL	Phase I, China
Non-Nucleoside Antivirals - Interfere with proteins involved in viral reproduction			

Myrcludex B	Entry Inhibitor	Hepatera, Russia with Myr-GmbH, Germany	Phase II for HBV and HDV
ARC520	RNAi gene silencer	Arrowhead Pharmaceuticals, Pasadena, CA	Phase II/III
NVR 3-778	Capsid inhibitor	Novira Therapeutics, Doylestown, PA	Phase IIa
Morphothiadin mesilate (GLS4)	Capsid inhibitor	Sunshine Lake Pharma of HEC, China	Phase II
IONIS-HBVRx	Antisense drug	Ionis Pharma, Carlsbad, CA	Phase II
SB 9200 HBV	RIG-1 and NOD2 agonist	Spring Bank Pharma, Milford, MA	Phase II
Rep 2139-Ca	HBsAg release inhibitor	REPLICor Inc., Canada	Phase II
ARB-1467	RNAi gene silencer	Tekmira, Canada	Phase II
ARC521	RNAi gene silencer	Arrowhead Pharmaceuticals, Pasadena, CA	Phase II/I
AIC 649	Capsid Inhibitor	AiCuris, Germany	Phase I
IONIS-HBV-LRx	Antisense drug	Ionis Pharma (w/ GSK), Carlsbad, CA	Phase I
EYP001	FXR agonist	Enyo Pharma France	Phase I
CpAMS	HBV Core Protein	Assembly Biosciences, NY, NY	Preclinical
ALN-HBV	RNAi gene silencer	Alnylam, Cambridge, MA	Preclinical
CPI-431-32	Cyclophilin inhibitor	Ciclofilin Pharma, San Diego, CA	Preclinical
Hepbarna	RNAi gene silencing	Benitec, Australia	Preclinical
ARB-1740	Gene silencer	Arbutus Biopharma Canada	Preclinical
Non-Interferon Immune Enhancers - Boost T-cell infection-fighting immune cells and natural interferon production			

ABX 203	Therapeutic vaccine	ABIVAX, Paris, France	Phase IIb/III
GS-4774	Therapeutic vaccine	Gilead Sciences with Globe Immune, Louisville, CO	Phase II
GS-9620	TLR7 agonist	Gilead Sciences, Foster City, CA	Phase II
RG7795 (formerly ANA773)	TLR7 agonist	Roche, Switzerland	Phase II
INO-1800	Therapeutic vaccine	Inovio, Blue Bell, PA	Phase I
NCT01641536	Therapeutic vaccine	Ichor Medical Systems (w/Janssen), San Diego, CA	Phase I
TG 1050	Immunotherapeutic	Transgene, Shanghai	Phase I
ARB-1598	TLR9 agonist	Arbutus Biopharma Canada	Phase I
Hepatitis Delta Virus (HDV) Drug Watch			
Myrcludex B	Entry Inhibitor (Targeting NTCP)	Hepatera, Russia with Myr-GmbH, Germany	"Orphan Drug Designation" by US FDA and EMA for HDV
Lonafarnib	Prenylation Inhibitor	Eiger BioPharmaceuticals, Palo Alto, CA	Phase II for HDV
Rep 2139	HBsAg Release Inhibitor	REPLICor, Canada	Phase II for HDV